Macrogenics (MGNX) EBIAT (2016 - 2025)
Macrogenics (MGNX) has disclosed EBIAT for 14 consecutive years, with -$14.2 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 8.21% to -$14.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$74.6 million, a 11.43% decrease, with the full-year FY2025 number at -$74.6 million, down 11.43% from a year prior.
- EBIAT was -$14.2 million for Q4 2025 at Macrogenics, down from $16.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $57.5 million in Q2 2023 to a low of -$66.4 million in Q1 2022.
- A 5-year average of -$23.6 million and a median of -$39.0 million in 2021 define the central range for EBIAT.
- Peak YoY movement for EBIAT: plummeted 2680.16% in 2021, then skyrocketed 239.14% in 2023.
- Macrogenics' EBIAT stood at -$58.0 million in 2021, then skyrocketed by 122.06% to $12.8 million in 2022, then tumbled by 459.88% to -$46.1 million in 2023, then skyrocketed by 66.53% to -$15.4 million in 2024, then rose by 8.21% to -$14.2 million in 2025.
- Per Business Quant, the three most recent readings for MGNX's EBIAT are -$14.2 million (Q4 2025), $16.8 million (Q3 2025), and -$36.3 million (Q2 2025).